Risk Factors Associated with Medications Sample Clauses

Risk Factors Associated with Medications. I understand that Leuprolide Acetate, or Lupron, will put me into a temporary menopausal state. For this reason, I have been told that I may begin to experience hot flashes after using the medication for about a week. Additionally, although most patients tolerate Lupron quite well, I have been told that some women report headaches or temporary bloating of the abdomen. I am aware that Lupron may also change the nature of my menstrual cycle. I have been told that my period may come earlier or later than I expect; the flow may also be heavier or lighter than usual. There have been no documented long-term side effects of Lupron. It has been explained to me that many women actually have a decrease in side effects once they start their active medications (Bravelle, Gonal-F, Follistim and Repronex), and that this is related to the increased estrogen in the blood stream during the stimulation phase, which decreases the side effects associated with Lupron. Although side effects can occur (see discussion of ovarian hyperstimulation, below), I have been informed that most women tolerate these medications well. I understand that, except for ovarian hyperstimulation (which will be described below), which can occasionally be caused by hCG (Profasi, Pregnyl or Novarel), there are virtually no known side effects associated with injections of hCG, and that most women tolerate this medication quite well. In addition to the above, I am aware that the use of the above medications can also cause side effects such as nausea, vomiting, hot flashes, headaches, mood swings and visual symptoms. Allergic reactions are also possible, but rare. I have been told that I may take Tylenol or Extra Strength Tylenol as needed for pain control. I have been warned to avoid taking Advil or any other brand of Ibuprofen, however. Should I feel the need to take any other form of medication, I have been asked to please contact the IVF Program first.
AutoNDA by SimpleDocs
Risk Factors Associated with Medications. I understand that Leuprolide Acetate, or Lupron, will put me into a temporary menopausal state. For this reason, I have been told that I may begin to experience hot flashes after using the medication for about a week. Additionally, although most patients tolerate Leuprolide Acetate quite well, I have been told that some women report headaches or temporary bloating of the abdomen. I am aware that Leuprolide Acetate may also change the nature of my menstrual cycle. I have been told that my period may come earlier or later than I expect; the flow may also be heavier or lighter than usual. There have been no documented long-term side effects of Leuprolide Acetate. It has been explained to me that many women actually have a decrease in side effects once they start their active medications (Bravelle, Gonal-F, Follistim, and Repronex) and that this is related to the increased estrogen in the blood stream during the stimulation phase, which decreases the side effects associated with Leuprolide Acetate. Although side effects can occur (see discussion of ovarian hyperstimulation, below), I have been informed that most women tolerate these medications quite well. Antagon and Cetrotide have not been associated with significant side effects, although on occasion, these medications may not prevent the release of the egg(s) from the ovaries prior to egg retrieval. I understand that, except for ovarian hyperstimulation (which will be described below), which can occasionally be caused by hCG (Profasi, Pregnyl, Ovidrel or Novarel), there are almost no known side effects associated with injections of hCG, and that most women tolerate this medication quite well. In addition to the above, I am aware that the use of the above medications can also cause side effects such as nausea, vomiting, hot flashes, headaches, mood swings and visual symptoms. Allergic reactions are also possible, but rare. I have been told that I may take Tylenol or Extra Strength Tylenol as needed for pain control. I have been warned to avoid taking Advil or any other brand of Ibuprofen, however. Should I feel the need to take any other form of medication, I have been asked to please contact the IVF Program first.

Related to Risk Factors Associated with Medications

  • Career Ladder Effective July 1, 2014, TALC and the District agreed to the 11 implementation of a Career Ladder for the advancement of instructional staff on the 12 Performance Salary Schedule. Elements of the Career Ladder are outlined and posted on 13 the District website and include detailed descriptions of Career Ladder levels and the 14 requirements for movement. All instructional staff hired on or after January 8, 2018 will 15 be placed on the Apprentice level of the Career Ladder.

  • Collocation Transfer of Responsibility Without Working Circuits The Collocation is not serving any End User Customers and does not have active service terminations (e.g., Interconnection trunks or UNE Loops) or 2) Collocation Transfer of Responsibility With Working Circuits – The Collocation has active service terminations, such as Interconnection trunks or is serving End User Customers.

  • SCOPE OF SERVICES/CASE HANDLING A. Upon execution by Xxxxxx, Attorneys are retained to provide legal services for the purpose of seeking damages and other relief in the Litigation. Client agrees that Xxxxxx may choose to associate additional law firm(s) and/or lawyer(s) to represent Client in connection with the investigation and prosecution of the rights Client has as a purchaser of publically traded securities of Xxxxxx, and Client understands that such representation shall be on the same terms as those described in this agreement.

  • Business Continuity Planning Supplier shall prepare and maintain at no additional cost to Buyer a Business Continuity Plan (“BCP”). Upon written request of Buyer, Supplier shall provide a copy of Supplier’s BCP. The BCP shall be designed to ensure that Supplier can continue to provide the goods and/or services in accordance with this Order in the event of a disaster or other BCP-triggering event (as such events are defined in the applicable BCP). Supplier’s BCP shall, at a minimum, provide for: (a) the retention and retrieval of data and files; (b) obtaining resources necessary for recovery, (c) appropriate continuity plans to maintain adequate levels of staffing required to provide the goods and services during a disruptive event; (d) procedures to activate an immediate, orderly response to emergency situations; (e) procedures to address potential disruptions to Supplier’s supply chain; (f) a defined escalation process for notification of Buyer, within two (2) business days, in the event of a BCP-triggering event; and (g) training for key Supplier Personnel who are responsible for monitoring and maintaining Supplier’s continuity plans and records. Supplier shall maintain the BCP and test it at least annually or whenever there are material changes in Supplier’s operations, risks or business practices. Upon Xxxxx’s written and reasonable request, Supplier shall provide Buyer an executive summary of test results and a report of corrective actions (including the timing for implementation) to be taken to remedy any deficiencies identified by such testing. Upon Xxxxx’s request and with reasonable advance notice and conducted in such a manner as not to unduly interfere with Supplier’s operations, Supplier shall give Buyer and its designated agents access to Supplier’s designated representative(s) with detailed functional knowledge of Supplier’s BCP and relevant subject matter.

  • Action Item Task MSU Status Comments I.1 The University will employ and empower a Clery Act compliance professional (CCP). The CCP must report to a Vice President (VP) or equivalent. The CCP must not be employed in or under the sole authority of the Office of the General Counsel (OGC). Implemented The Office of Audit, Risk and Compliance (OARC) hired a qualified candidate who began work in February 2020.

  • Procedures for Providing NP Through Full NXX Code Migration Where a Party has activated an entire NXX for a single Customer, or activated at least eighty percent (80%) of an NXX for a single Customer, with the remaining numbers in that NXX either reserved for future use by that Customer or otherwise unused, if such Customer chooses to receive Telephone Exchange Service from the other Party, the first Party shall cooperate with the second Party to have the entire NXX reassigned in the LERG (and associated industry databases, routing tables, etc.) to an End Office operated by the second Party. Such transfer will be accomplished with appropriate coordination between the Parties and subject to appropriate industry lead times for movements of NXXs from one switch to another. Neither Party shall charge the other in connection with this coordinated transfer.

  • COVID-19 Residents acknowledge that in March 2020 the World Health Organization declared a global pandemic of the virus leading to COVID-19. The Governments of Canada, the Province of Ontario, and local Governments responded to the pandemic with legislative amendments, controls, orders, by-laws, requests of the public, and requests and requirements to Humber (collectively, the “Directives”). It is uncertain how long the pandemic, and the related Directives, will continue, and it is unknown whether there may be a resurgence of the virus leading to COVID-19 or any mutation thereof (collectively, “COVID- 19”). Without limiting the generality of the foregoing paragraph, Humber shall not be held legally responsible or be deemed to be in breach of this Agreement for any damages or loss arising out of or caused by:

  • Budget Information Funding Source Funding Year of Appropriation Budget List Number Amount EPIC 18-19 301.001F $500,000 EPIC 20-21 301.001H $500,000 R&D Program Area: EDMFO: EDMF TOTAL: $ 1,000,000 Explanation for “Other” selection Reimbursement Contract #: Federal Agreement #:

  • Proposing Integration Activities in the Planning Submission No integration activity described in section 6.3 may be proposed in a CAPS unless the LHIN has consented, in writing, to its inclusion pursuant to the process set out in section 6.3(b).

  • Plan Information The Employee agrees to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with Applicable Laws outside the United States, from the Long-term Incentives website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the investor relations section of the Company's website at xxx.xx.xxx. The Employee acknowledges that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Company Secretary. The Employee hereby consents to receive any documents related to current or future participation in the Plan by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

Time is Money Join Law Insider Premium to draft better contracts faster.